To study the efficacy and safety of ritonavir-boosted lonafarnib, with or without peginterferon alfa, the phase 3 D-LIVR study enrolled 407 individuals diagnosed with compensated liver disease linked to CHD being treated with NA therapy who had achieved HBV DNA suppression for at least 12 weeks, and presented with elevated serum ALT levels (>1.3 × ULN and <10 × ULN). The gene discussed is GPT; the disease is liver disorder.